105 S. State Street #401
Orem,  UT  84058

United States
  • Booth: 4701

Founded in 2013, Techcyte is transforming manual microscopy with powerful artificial intelligence that automates lab diagnostic testing and improves the results and work environment of lab professionals. Techcyte’s clinical pathology AI platform increases accuracy, streamlines testing workflows, eases staffing challenges, and saves precious time in the delivery of diagnoses. Techcyte is revolutionizing diagnostic testing for humans, animals and the environment.

 Press Releases

  • Techcyte announced today a strategic collaboration with Mayo Clinic to create new AI algorithms and workflows on the Techcyte Clinical Pathology AI Platform.

    Techcyte’s Clinical Pathology AI Platform imports digital images of liquid-based samples acquired through whole slide scanners. These images are analyzed by deep learning algorithms that identify and classify target objects. The resulting images are verified by medical technologists after which the results are exported to lab information systems.

    Techcyte AI experts will collaborate with Mayo Clinic on developing diagnostic testing with increased accuracy and efficiency to positively impact the practice of lab medicine and the patients that depend on the results.

    “Mayo Clinic’s model of integrated care gives us unique data and expertise that, when combined with Techcyte’s AI platform, will produce diagnostics that can potentially revolutionize how lab medicine is practiced. This collaboration is another step in the transformation of health care to a platform model that benefits patients,” stated William G. Morice II, M.D., Ph.D., CEO and President of Mayo Clinic Laboratories.

    “We’re honored and excited to be collaborating with Mayo Clinic,” said Ben Cahoon, CEO of Techcyte. “The comprehensive vision and plans for enhancing laboratory medicine and taking digital pathology to the world is remarkable.”

    Mayo Clinic has a financial interest in the technology referenced in this press release. Mayo Clinic will use any revenue it receives to support its not for-profit mission in patient care, education and research.

  • Techcyte is proud to announce the completion of initial validation studies for its artificial intelligence-powered Bladder Cancer screening solution. These studies suggest that its deep machine-learning algorithm is capable of classifying objects of interest and detecting cancerous cells. Validation studies were conducted using samples treated with a proprietary staining technique developed by CytoBay Labs, Techcyte’s development partner for this product.

    “Our goal at Techcyte is to create a comprehensive AI model to assist lab professionals in making more accurate and efficient reads,” says Chris Summerhays, Techcyte Product Manager. “We are excited to be one step closer to being able to do that for bladder cancer screening tests with the completion of our initial AI validation and clinical studies.” 

    Initial results from a single hospital-based clinical study of 150 patients with various clinical conditions show that when coupled with CytoBay’s proprietary stain, Techcyte’s solution achieved a sensitivity of up to 98% and specificity of up to 85%*. Additional laboratory validation will now be conducted to further prove the test’s efficiency and accuracy.

    “We are pleased with the initial results,” says Dr. Wenjiang Chu, MD, PhD, CytoBay Founder. “The success we’ve seen in combining Techcyte’s technology with CytoBay’s proprietary staining solution is promising. It’s proving to be reliable, cost-effective, and convenient for lab professionals and patients alike.”

    In 2022, 870,910 bladder cancer survivors in the U.S. needed recurring cancer surveillance. The current gold standard for this type of surveillance is invasive, costly, and time-consuming, leaving many survivors to opt out of the procedure. 

    This partnership will introduce the first Bladder Cancer screening test coupled with AI; however, the product requires further validation. It is still in the research phase as it progresses towards a full clinical validation and a FDA submission. The goal is to use the product to provide initial results for those who have no prior diagnosis and maintenance results for those who have had cancer, gone through treatment, and require recurring surveillance tests. If a positive result is found through Techcyte’s urine test, future biopsies can then be conducted.

    Techcyte and CytoBay’s Bladder Cancer Screening Solution is for Research Use Only and is in the data gathering and study design phase. It has not been evaluated by the FDA, and Techcyte plans to perform a broader study before submitting for FDA clearance. 

    *This claim has not yet been examined by the FDA.

  • Artificial Intelligence Super-Resolution Image Reconstruction Is a Promising Solution to Reduce Cost of Digital Pathology Image Storage

    Techcyte has developed AI super-resolution image reconstruction that provides a solution to reduce digital pathology image storage cost. Techcyte presented a poster on the subject at the United States and Canadian Academy of Pathology (USCAP) conference this week in New Orleans. 

    Techcyte’s Clinical Pathology AI Platform uses artificial intelligence (AI) to make predictions for various diagnostic tests. This process includes digitizing slides with a whole-slide scanner and uploading the images to the Techcyte platform. However, the cost associated with storing large numbers of full-resolution whole-slide images can be significant. 

    “We’re proposing the use of super-resolution technology to reconstruct high resolution views of images that are downsized to reduce storage costs for laboratories and hospitals,” says Rick Smith, Techcyte President. “These preliminary results show promise that downsized images can provide significant cost savings without compromising clinical results.”

    In the poster, Techcyte performed a comparative analysis between super-resolution images and 4X up-scaled images using traditional methods to demonstrate the improved appearance of super-resolution images. The study showed that super-resolution images maintained a high degree of similarity with the original high-resolution reference images. 

    For additional information, you can view the poster here

  • Techcyte, the developers of the Clinical Pathology AI Platform, added powerful platform workflow enhancements (profiles and post model processing) to improve the flexibility and efficiency of digital diagnostic workflows for parasitology, bacteriology, hematology, cervical cytology, and bladder cancer surveillance.

    All clinical laboratories are facing labor shortages, and the problem is compounded because microscopic analysis can take upwards of 5 to 10 minutes per slide. Techcyte’s new workflow technology saves laboratories time and money by organizing the raw image data presented by the AI into a customizable, efficient workflow that reduces analysis time to 15 to 30 seconds*.  

    This new post model processing enables medical technologists to apply rules to objects that the algorithms identify. This includes class remapping, dynamic display of classes and objects, semi-quantitative grading, chart display, and ruleset management. The rules can be based on size, morphology, and other attributes associated with each class. 

    For example, semi-quantitative ranges for the Techcyte peripheral blood smear classifier can be changed for each customer to match their protocols and populations. Band neutrophils can also be graded separately or combined with segmented neutrophils as desired. Sample profiles can also be created to tag samples with percentages in various ranges.  

    “Our AI is great at analyzing pixels and proposing high confidence targets, but the proposals adapt to the existing workflow to achieve the efficiency gains that labs need,” said Rick Smith, Techcyte President. “The workflow platform that we have built around our AI algorithms makes Techcyte solutions flexible, efficient, and able to integrate with lab information systems to better meet our customers’ needs.”

    Techcyte’s parasitology, bacteriology, hematology, cervical cytology, and bladder cancer surveillance products are currently for Research Use Only in the U.S.

    *This claim has not yet been examined by the FDA.

 Additional Info

We will be displaying a new product or promoting a new indication/enhanced feature for an existing product in our booth?
Included in the Export Interest Directory?